Symbiotix Biotherapies has entered into a license agreement with Harvard University. Under the agreement, Symbiotix gains access to a portfolio of intellectual property developed in the laboratory of Dennis Kasper, M.D., William Ellery Channing Professor of Medicine and Professor of Microbiology and Immunobiology at Harvard Medical School.   Drawing on aspects of Dr. Kasper’s earlier research at Brigham & Women’s Hospital, Symbiotix developed Reglemers™, a new class of molecular ther...